Womenra: Restore Female Sexual Desire with Flibanserin
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.30 | $43.00 (0%) | 🛒 Add to cart |
| 20 | $2.58 | $86.00 $51.60 (40%) | 🛒 Add to cart |
| 30 | $2.01 | $129.00 $60.20 (53%) | 🛒 Add to cart |
| 60 | $1.29 | $258.00 $77.40 (70%) | 🛒 Add to cart |
| 90 | $1.05 | $387.00 $94.60 (76%) | 🛒 Add to cart |
| 120 | $1.00 | $516.00 $120.40 (77%) | 🛒 Add to cart |
| 180 | $0.86 | $774.00 $154.80 (80%) | 🛒 Add to cart |
| 270 | $0.76 | $1161.00 $206.40 (82%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $1548.00 $258.00 (83%) | 🛒 Add to cart |
Womenra is a prescription medication specifically developed to address acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It contains flibanserin, a multifunctional serotonin agonist and antagonist that works centrally to rebalance neurotransmitters associated with sexual interest. Unlike hormonal therapies, Womenra targets the brain’s neurochemistry to help restore natural desire, reduce distress related to low libido, and improve satisfying sexual events. It represents a clinically validated, non-hormonal option for women seeking to reclaim their sexual wellbeing.
Features
- Active ingredient: Flibanserin 100mg
- Form: Oral tablet
- Mechanism: Central serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist
- Prescription-only status
- Manufactured under strict pharmaceutical quality controls
- Packaged with moisture-resistant blister packs
Benefits
- Increases the number of satisfying sexual events per month
- Reduces distress associated with low sexual desire
- Restores natural libido through neurochemical modulation
- Non-hormonal mechanism of action
- Clinically validated efficacy in premenopausal women
- Improves overall sexual satisfaction and intimacy
Common use
Womenra is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by a persistent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by another medical condition, substance use, or severe relationship distress. It is intended for women who have previously experienced a satisfactory level of sexual desire but have developed persistent low desire despite adequate stimulation.
Dosage and direction
The recommended dosage is one 100mg tablet taken orally once daily at bedtime. Administration at bedtime is crucial due to the potential for dizziness, sedation, and hypotension. Tablets should be swallowed whole with water and not crushed or chewed. Consistent daily dosing is necessary for therapeutic effect, which may become noticeable after 4-8 weeks of continuous use. Treatment should be discontinued after 8 weeks if no meaningful improvement in sexual desire and associated distress is observed.
Precautions
Patients should avoid alcohol consumption during treatment with Womenra due to the risk of severe hypotension and syncope. Caution is advised when operating hazardous machinery or driving until the individual response to the medication is established. Hepatic impairment requires dosage adjustment or avoidance. Blood pressure monitoring is recommended, particularly during initial treatment phases. Patients should be advised about the potential for dizziness and lightheadedness, especially when standing up quickly from sitting or lying positions.
Contraindications
Womenra is contraindicated in patients with hepatic impairment. Concomitant use with strong or moderate CYP3A4 inhibitors is prohibited. It should not be used in postmenopausal women or men. Patients with a history of hypotension or syncope should avoid this medication. Concomitant use with alcohol is absolutely contraindicated. Womenra is not recommended for patients taking other central nervous system depressants. Pregnancy and breastfeeding constitute absolute contraindications due to unknown fetal risks.
Possible side effects
Common adverse reactions include dizziness (12%), somnolence (11%), nausea (8%), fatigue (7%), and insomnia (5%). Less frequently reported effects include dry mouth, anxiety, and hypotension. Approximately 13% of patients discontinue treatment due to adverse effects, primarily during the first two weeks of therapy. Syncope occurs in approximately 0.4% of patients, particularly with alcohol co-consumption. Most side effects are dose-dependent and may diminish with continued treatment.
Drug interaction
Womenra is primarily metabolized by CYP3A4 and CYP2C19 enzymes. Concomitant use with strong CYP3A4 inhibitors (ketoconazole, itraconazole) is contraindicated. Moderate CYP3A4 inhibitors (fluconazole, verapamil) require dosage reduction to 50mg daily. CYP2C19 inhibitors may increase flibanserin exposure. Concurrent use with other CNS depressants (benzodiazepines, opioids) may potentiate sedation. Serotonergic drugs may increase the risk of serotonin syndrome. Antihypertensive medications may exacerbate hypotensive effects.
Missed dose
If a dose is missed at the usual bedtime time, patients should skip the missed dose and resume regular dosing schedule the following night. Doubling the dose to make up for a missed dose is not recommended due to increased risk of adverse effects. Patients should maintain the regular once-daily dosing regimen without interruption for optimal therapeutic effect.
Overdose
Symptoms of overdose may include severe dizziness, profound sedation, hypotension, and syncope. There is no specific antidote for flibanserin overdose. Management should include supportive care with continuous blood pressure and heart rate monitoring. Gastric lavage may be considered if ingestion occurred within 1-2 hours. Intravenous fluids and vasopressors may be required for significant hypotension. Patients should be monitored for at least 24 hours due to the drug’s half-life of approximately 11 hours.
Storage
Store at room temperature (20-25°C or 68-77°F) in the original blister packaging to protect from moisture. Keep container tightly closed and away from direct sunlight. Do not store in bathrooms or other humid areas. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of unused medication through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Womenra is available by prescription only after thorough evaluation by a qualified healthcare provider. Individual results may vary, and not all patients will experience the described benefits. Patients should discuss their complete medical history, including all medications and supplements, with their healthcare provider before starting treatment. Regular follow-up appointments are essential to monitor treatment efficacy and safety.
Reviews
Clinical trial data demonstrate that 46-60% of women treated with Womenra experience meaningful improvement in sexual desire and distress scores compared to 29-38% with placebo. Patients report an average increase of 0.8-1.2 satisfying sexual events per month over baseline. Quality of life measures show significant improvement in relationship satisfaction and personal distress. Many users note the importance of patience, as therapeutic effects typically emerge after 4 weeks of consistent use. Healthcare providers emphasize the necessity of strict alcohol avoidance and bedtime dosing for optimal safety profile.